Document is current

Article History

Received: 27 February 2025

Revised: 21 July 2025

Accepted: 18 August 2025

First Online: 30 August 2025

Competing interests

: ER reports grants (institutional) from Gilead and Menarini; travel, accommodations, and expenses fees from Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, Novartis and Menarini; honoraria (institutional) for lectures, presentations, consultancy from Eli Lilly, Seagen, Novartis, Astrazeneca, and Menarini; all outside the scope of the submitted work. SD: Consulting or Advisory Role: AstraZeneca, Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Puma (Inst), Eli Lilly (Inst), Novartis (Inst), Sanofi (Inst). Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Roche. YS and BL are employees of Cegedim. TP: Travel and accommodation fees from Servier and Viatris outside the submitted work. AB: Consulting or Advisory Role, Travel, Accommodations, Expenses: Mercks, Viatris, Ipsen, Servier. SM reports personal fees from Scientific Committee Study member to Roche, Data and safety monitoring member of clinical trials: IQVIA, Kedrion, Biophytis, Servier, Yuhan, all outside the scope of the submitted work. MK: None relevant to this study.

: THIN® comprises electronic medical records compliant with the European General Data Protection Regulations (GDPR). This study was examined and approved by THIN® Scientific Review Committee (protocol number 20 002 R1).

: This is a retrospective data of THIN® comprises electronic medical records compliant with the European general data protection regulations (GDPR). A consent to publish this manuscript was not required.